Unknown

Dataset Information

0

Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.


ABSTRACT: Controversy exists over antidepressant use in bipolar II depression.To compare the safety and effectiveness of antidepressantv.mood stabiliser monotherapy for bipolar type II major depressive episodes.Randomised, double-blind, parallel-group, 12-week comparison of venlafaxine (n= 65)v.lithium (n= 64) monotherapy in adult out-patients (trial registration numberNCT00602537).Primary outcome - venlafaxine produced a greater response rate (67.7%)v lithium (34.4%,P<0.001). Secondary outcomes - venlafaxine produced a greater remission rate (58.5%v 28.1%,P<0.001); greater decline in depression symptom scores over time (? = -5.32, s.e. = 1.16, ?(2)= 21.19,P<0.001); greater reduction in global severity scores over time (? = -1.05, s.e. = 0.22, w(2)= 22.33,P<0.001); and greater improvement in global change scores (? = -1.31, s.e. = 0.32, ?(2)= 16.95,P<0.001) relative to lithium. No statistically significant or clinically meaningful differences in hypomanic symptoms were observed between treatments.These findings suggest that short-term venlafaxine monotherapy may provide effective antidepressant treatment for bipolar II depression without a statistically significant increase in hypomanic symptoms relative to lithium.

SUBMITTER: Amsterdam JD 

PROVIDER: S-EPMC4816972 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.

Amsterdam Jay D JD   Lorenzo-Luaces Lorenzo L   Soeller Irene I   Li Susan Qing SQ   Mao Jun J JJ   DeRubeis Robert J RJ  

The British journal of psychiatry : the journal of mental science 20160218 4


<h4>Background</h4>Controversy exists over antidepressant use in bipolar II depression.<h4>Aims</h4>To compare the safety and effectiveness of antidepressantv.mood stabiliser monotherapy for bipolar type II major depressive episodes.<h4>Method</h4>Randomised, double-blind, parallel-group, 12-week comparison of venlafaxine (n= 65)v.lithium (n= 64) monotherapy in adult out-patients (trial registration numberNCT00602537).<h4>Results</h4>Primary outcome - venlafaxine produced a greater response rate  ...[more]

Similar Datasets

| S-EPMC3613721 | biostudies-literature
| S-EPMC2801829 | biostudies-other
| S-EPMC5182117 | biostudies-literature
| S-EPMC4879786 | biostudies-literature
| S-EPMC6246657 | biostudies-literature
| S-EPMC5109991 | biostudies-literature
| S-EPMC10283309 | biostudies-literature
| S-EPMC6161980 | biostudies-literature
| S-EPMC4510385 | biostudies-other
| S-EPMC8593846 | biostudies-literature